Immunological considerations regarding parental concerns on pediatric immunizations

Francesco Nicoli, Victor Appay

► To cite this version:

Francesco Nicoli, Victor Appay. Immunological considerations regarding parental concerns on pediatric immunizations. *Vaccine*, 2017, 35 (23), pp.3012 - 3019. 10.1016/j.vaccine.2017.04.030 . hal-01529332

HAL Id: hal-01529332

<https://hal.sorbonne-universite.fr/hal-01529332>

Submitted on 30 May 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Immunological considerations regarding parental concerns on pediatric**
2 **immunizations**

3 Francesco Nicoli^{a,b}, Victor Appay^{a,b}

4 ^a Sorbonne Universités, UPMC Univ Paris 06, DHU FAST, CR7, Centre d'Immunologie et des Maladies
5 Infectieuses (CIMI-Paris), Paris, France

6 ^b INSERM, U1135, CIMI-Paris, Paris, France

7 Correspondance to

8 Francesco Nicoli, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), 91 bd de l'Hopital, 75013
9 Paris, France. E-mail address: francesco.nicoli@upmc.fr.

10

11

12 **Abstract**

13 Despite the fundamental role of vaccines in the decline of infant mortality, parents may decide to decline
14 vaccination for their own children. Many factors may influence this decision, such as the belief that the infant
15 immune system is weakened by vaccines, and concerns have been raised about the number of vaccines and the
16 early age at which they are administered. Studies focused on the infant immune system and its reaction to
17 immunizations, summarized in this review, show that vaccines can overcome those suboptimal features of
18 infant immune system that render them more at risk of infections and of their severe manifestations. In
19 addition, many vaccines have been shown to improve heterologous innate and adaptive immunity resulting in
20 lower mortality rates for fully vaccinated children. Thus, multiple vaccinations are necessary and not
21 dangerous, as infants can respond to several antigens as well as when responding to single stimuli. Current
22 immunization schedules have been developed and tested to avoid vaccine interference, improve benefits and
23 reduce side effects compared to single administrations. The infant immune system is therefore capable, early
24 after birth, of managing several antigenic challenges and exploits them to prompt its development.

25
26
27
28
29 **Key words:** vaccine; children; heterologous effect; pediatric immunization.

30

31 **1. Introduction**

32 Despite the fundamental role of vaccines in the decline of infant mortality [1], the decision of vaccinating one's
33 own children is often made with some anxiety [2]. Concerns are varied and include the safety of single vaccine
34 components, the age at first immunization (i.e. too early) or the number of vaccines (i.e. too many) [2]. Severe
35 adverse reactions are extremely rare [3], but parents may have more general worries regarding the capacity of
36 such a young immune system to bear immunizations. The aim of this review is to summarize key concepts of
37 human immunology and vaccinology to understand the reaction of the early age immune system to vaccines.

38 **2. Vaccine-specific immune responses in children**

39 **2.1 Development of vaccine-specific immunity**

40 The development of adaptive memory responses, which are the primary target of immunizations, needs the
41 initial triggering by innate cells such as professional antigen presenting cells (APC). However, this step is
42 defective in early age [4]: newborn antigen presenting cells are low in number, immature, respond poorly to
43 activation via Pattern Recognition Receptors (PRR) and provide modest co-stimulation [Reviewed in 5, 6]. As a
44 consequence, primary CD8 and CD4 responses may be weaker [Reviewed in 7, 8] and show a bias toward a Th2
45 phenotype [Reviewed in 7, 8], which is then reverted through booster doses and adjuvants [9, 10].

46 Nevertheless, the development of a memory pool is not prevented, even in subjects with undetectable effector
47 responses [11].

48 The immaturity of secondary lymphoid organs [12, 13] limits the development of humoral responses at early
49 age, which are lower in magnitude and shorter in duration [Reviewed in 14]. Nonetheless, the development of
50 memory B cells is not compromised and may occur even in subjects with low antibody titers [15, 16]. In
51 addition, infants below the third month of age are unable to generate antibody responses against those

antigens that do not require T cell help (e.g. polysaccharides) [17, 18], a problem overcome through their conjugation with proteins [19].

The overall immaturity of infant immune system (summarized in Fig. 1 and Table S1), which was necessary to ensure maternofetal tolerance [18], results in lower vaccine responses than those developed in adults [20], save some relevant exceptions [21-23]. However, the primary aim of pediatric vaccines is not to develop adult-like immune responses (which will be reached through boosting doses [24, 25]), but rather to induce protective immunity, and data show that protective antibody titers may be elicited in more than 90% of children at 7 months of age against individual immunogens such as Polio, diphtheria-tetanus-pertussis (DTP), haemophilus influenzae type B (Hib), Hepatitis B virus (HBV) and Pneumococcal conjugate vaccine (PCV) [26]. Indeed, newborns can still develop innate and adaptive responses against the enormous number of microorganisms met since the delivery or even in utero [27-29] and vaccine-specific B and T immune responses already within hours after birth [30, 31], demonstrating that even if some immune functions may be suboptimal in early age, they are sufficiently developed to mount protective responses and generate effective memory cells [11, 15, 16], the final targets of vaccines. In addition, adjuvants and formulation efforts may help an immature immune system to develop vaccine-specific responses that would not be elicited by natural infections [19].

2.2 Indirect effects of vaccine-specific immunity

The importance of vaccine-specific responses goes beyond the simple prevention of the infections targeted by the immunization (Table 1). For instance, vaccine-induced epitope-specific responses towards one virus may show cross protection against other viral genotypes [32] or viruses of the same family [33]. Prevention of heterologous infections also occurs by avoiding the immunosuppressive effects exerted by pathogens such as varicella, influenza or measles [34-36]. Vaccine-preventable infections are often involved in other pathologies; for instance, respiratory infections and Bordetella pertussis contribute to sudden infant death syndrome (SIDS) [37-39]. Indeed, whilst several modifiable (e.g. sleeping position, type of bed and bedclothes) and non-

75 modifiable (e.g. genetic) risk factors are associated with SIDS [38], its incidence is lowered after vaccination
76 against DTP, Hib and pneumococcal bacteria [39-41].

77 **3. Non-specific immune responses elicited by vaccines**

78 Several studies have shown that exposure to infectious agents may alter the immune response to unrelated
79 infections [42]. Consistently, vaccines have been shown to affect, on a long term temporal frame, innate
80 immunity (that has recently shown memory-like properties referred to as “trained immunity”) as well as
81 adaptive immunity toward unrelated antigens [43, 44].

82 **3.1 Adjuvant effect**

83 Bacillus Calmette–Guérin (BCG) vaccine induces a strong polyclonal stimulation, boosts APC and lymphocyte
84 functions [44-46] and increases responses toward vaccines administered at the same moment [47] or even
85 later [48, 49]. In addition, BCG vaccine is used as an immunotherapeutic treatment against cancer and has been
86 shown to prevent lymphoma and leukemia [45, 50].

87 **3.2 Effect towards heterologous infections**

88 BCG and, most likely, measles-mumps-rubella (MMR) vaccines favor the development of macrophage and
89 monocyte functions [44, 51, 52] as well as lymphocyte responses [44, 48, 52, 53]. This has been associated with
90 a lower incidence of infections [54-56], particularly at the level of the respiratory tract [57-59]. Conversely,
91 alum-adjuvanted DTP vaccines induce preferentially Th2-responses [60, 61] and are associated with increased
92 susceptibility to infections [54, 55, 62]. However, this effect is controversial, as some studies found a protective
93 role or a lack of association [57, 63, 64].

94 **3.3 Effect on atopic disorders and autoimmune diseases**

95 Historically, vaccines have been proposed to be involved in the development of allergies, asthma and other
96 atopic disorders [65]. However, while this association has not been confirmed [66-68], it has been shown that

97 protection towards heterologous respiratory infections through direct and indirect mechanisms may decrease
98 the risk of asthma, in particular with MMR [69, 70] and BCG [71, 72] vaccines. Moreover, as atopic disorders
99 are associated with Th2-type responses [73], vaccines favoring a Th1 phenotype (such as BCG or MMR) might
100 be protective [72]. Conversely, although some studies found also a protective role for inactivated vaccines [68,
101 74], others reported lack of association or even a negative effect [75, 76].

102 Vaccines have also been considered as potential causes of autoimmune diseases (AIDs), in particular due to
103 adjuvants responsible for the “autoimmune/inflammatory syndrome induced by adjuvants” (ASIA) [77, 78].
104 This topic is quite controversial: while case reports were published [77, 78], cohort studies showed a lack of
105 association between vaccinations and AIDs [79].

106 **3.4 Effect on overall mortality**

107 The capacity of some vaccines (i.e. BCG [80-82], MMR [80, 82], Smallpox [83] and Polio [84] vaccines) to
108 prevent unrelated infections results in a lower mortality rate. Conversely, it has been proposed that DTP
109 vaccine might be associated with a higher mortality rate, although results are not consistent between studies
110 [56, 80, 82, 85-90]. WHO concluded that evidence is insufficient to support any association of DTP vaccine with
111 overall mortality [82].

112 **4. Concerns leading to “personalized” immunization schedules**

113 The fear that infant immune system may be weakened by vaccines leads to “personalized” immunization
114 schedules where vaccines against those diseases believed not so harmful or easy to contract are delayed or
115 avoided. This attitude jeopardizes the health of children for all their lifetime [91, 92], as well as of the
116 community where they live [93], including the grandparents [94], newborn siblings [95] and the mother herself
117 [92].

118

119

120 **4.1 Are vaccines weakening the immune system?**

121 The above reported scientific evidence (summarized in Tables 1 and S2) argues against a deleterious effect of
122 vaccines on the infant immune system, showing rather that vaccines behave as other environmental factors
123 (microbes or nutrients), in accordance with the hygiene hypothesis, favoring the development of the immune
124 system [96, 97]. Indeed, children with complete vaccination coverage show, compared to unvaccinated or
125 poorly vaccinated pairs, a lower mortality rate and a general better health status [98-102].

126 **4.2 My child is so young, should I delay vaccinations?**

127 Current vaccination schedules, although they may vary between countries, recommend immunizations directly
128 after birth with HBV and BCG vaccines (and eventually oral polio vaccine, OPV), and at 2 months with DTP, Hib,
129 PCV, rotavirus vaccine (RV) and inactivated polio vaccine (IPV). Often parents prefer to postpone
130 immunizations to wait for a “more mature” immune system [103]. This may leave children unimmunized for
131 years. Indeed, while the immune system rapidly develops some functions at the time of first dose, i.e. two-
132 three months after birth [18, 104, 105], other properties (such as balanced IgG1 and IgG2 production) may
133 reach adult-levels at 1 year [104, 106, 107] or even during adolescence, as in the case of IL12 production [104,
134 108, 109]. In addition, the suboptimal features of the infant immune system that may argue against early life
135 vaccination are the same that render infants more susceptible to infections [6, 110]: natural infections induce,
136 in infants, poor Th1 and T-independent antibody responses which are instead elicited by vaccines [10, 19, 111].
137 Thus, postponing the first dose of vaccines: i) may have low to no effect on immunogenicity [112]; ii) may
138 increase the risks of adverse events [113], of never completing the vaccination course [103, 114] and of
139 modifying the order of immunizations with possible negative health outcomes [57, 115]; iii) and, most of all,
140 will leave children unprotected in a very risky period. For instance, a delay in initiating the diphtheria-tetanus-
141 acellular pertussis (DTaP) immunization program may double hospitalizations [116-118] as the first dose
142 administered at 2 months of age already confers considerable protection (from 50% to 75% or more) [118-
143 120].

144 **4.3 Are multiple immunizations overwhelming the immune system?**

145 Co-administration of vaccines is possible in two ways: combined vaccination (several antigens formulated in
146 one single vaccine) and simultaneous administration (more than one vaccine is administered concurrently but
147 at different anatomic sites). Simultaneous administration may be less compliant [121] compared to combined
148 vaccination, but it lowers the risk of interference between vaccines [122]. The latter may be positive, as for
149 vaccines comprising antigens and adjuvants at the same time [21, 47, 123], or negative, as was shown with the
150 combination of MMR and varicella vaccines (MMRV) [124]. This specific problem was later solved, mostly by
151 changing the doses of single components, to achieve for MMRV vaccine administration the same level of
152 immunogenicity as when MMR and varicella vaccines are administered separately [125]. Vaccines may
153 interfere at the level of the formulation or, when injected, at the level of immune responses, for instance
154 through polyclonal stimulation by one component or competition for cross-specific responses. It has been
155 proposed that live vaccines should be administered with a minimum of 28 days of time gap [122] to avoid
156 negative interferences [126]; however, this concept has been challenged in some studies [127, 128].
157 Conversely, negative interferences seem not to affect inactivated vaccines [129, 130].
158 Current immunization schedules are tested to avoid vaccine-specific interactions and show that infants may
159 efficiently respond to up to 10 vaccines (each of them composed of several antigens) at the same time [131,
160 132]. This demonstrates that multiple vaccinations do not exhaust immune resources, and are a safe practice
161 [133]. This concept is proved in children with mild diseases that have comparable vaccine responses as healthy
162 pairs [134-136]. Indeed, the huge repertoire of B- and T- cell specificity renders the immune system capable of
163 recognizing and facing different threats at the same time. It has been assumed that as much as 11 vaccines
164 given at the same time will exploit only the 0.1% of the B cell response [137].

165 **5. Conclusion**

166 The tremendous benefits that immunizations have on children's health may be undermined by personal risky
167 choices (not doing or delaying vaccinations) driven by some misconceptions such as: i) underestimating life
168 threatening diseases or the functionality of an early age immune system; ii) overestimating vaccine side effects.
169 Complete and reliable lists of adverse events connected to immunizations may be easily found (Box 1) to
170 inform parents. Conversely, the understanding of the interaction between the early age immune system and
171 vaccines is a more complex issue that involves several notions of immunology and vaccinology, and inadequate
172 answers to parents' doubts on these topics may have deleterious effects on immunization programs. Parents
173 should be reassured by current evidence demonstrating direct and indirect benefits of vaccines, such as a
174 decrease in overall morbidity and mortality from pediatric age, and a positive role in the development of the
175 immune system (Table 1). The knowledge of these indirect effects, the awareness of the threats that some
176 vaccine-preventable diseases pose especially in early age, and a correct understanding of infant immunity may
177 thus provide the basis to avoid the counterproductive decision of underimmunization (such as delaying
178 vaccinations or avoiding multiple immunizations, see Table 2). This decision, although taken with the good
179 intention to safeguard one's own children, may easily put at risk their life and the health of surrounding
180 people.

181

182

183

184 **Conflict of interest statement**

185 None.

186

187 **Acknowledgements**

188 This work was supported by the French Agence Nationale de la Recherche (ANR; project ANR-14-CE14-0030-
189 01). We would like to thank Justin Frere for editorial assistance.

190 **References**

- 191 [1] Lernout T, Theeten H, Leuridan E, Van Damme P. Do vaccines save lives? Yes they do! *Acta Med Port*
192 2014;27:160-2.
- 193 [2] Alfredsson R, Svensson E, Trollfors B, Borres MP. Why do parents hesitate to vaccinate their children against
194 measles, mumps and rubella? *Acta Paediatr* 2004;93:1232-7.
- 195 [3] Maglione MA, Das L, Raaen L, Smith A, Chari R, Newberry S, et al. Safety of vaccines used for routine
196 immunization of U.S. children: a systematic review. *Pediatrics* 2014;134:325-37.
- 197 [4] Matthews NC, Wadhwa M, Bird C, Borrás FE, Navarrete CV. Sustained expression of CD154 (CD40L) and
198 proinflammatory cytokine production by alloantigen-stimulated umbilical cord blood T cells. *J Immunol*
199 2000;164:6206-12.
- 200 [5] Kollmann TR, Levy O, Montgomery RR, Goriely S. Innate immune function by Toll-like receptors: distinct
201 responses in newborns and the elderly. *Immunity* 2012;37:771-83.
- 202 [6] Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. *Nat Rev Immunol*
203 2007;7:379-90.
- 204 [7] Marchant A, Goldman M. T cell-mediated immune responses in human newborns: ready to learn? *Clin Exp*
205 Immunol 2005;141:10-8.
- 206 [8] Adkins B, Leclerc C, Marshall-Clarke S. Neonatal adaptive immunity comes of age. *Nat Rev Immunol*
207 2004;4:553-64.
- 208 [9] Rieber N, Graf A, Hartl D, Urschel S, Belohradsky BH, Liese J. Acellular pertussis booster in adolescents
209 induces Th1 and memory CD8+ T cell immune response. *PLoS One* 2011;6:e17271.
- 210 [10] Barrios C, Brandt C, Berney M, Lambert PH, Siegrist CA. Partial correction of the TH2/TH1 imbalance in
211 neonatal murine responses to vaccine antigens through selective adjuvant effects. *Eur J Immunol*
212 1996;26:2666-70.

213 [11] Ausiello CM, Lande R, Urbani F, la Sala A, Stefanelli P, Salmaso S, et al. Cell-mediated immune responses in
 214 four-year-old children after primary immunization with acellular pertussis vaccines. *Infect Immun*
 215 1999;67:4064-71.

216 [12] Kruschinski C, Zidan M, Debertin AS, von Horsten S, Pabst R. Age-dependent development of the splenic
 217 marginal zone in human infants is associated with different causes of death. *Hum Pathol* 2004;35:113-21.

218 [13] Pihlgren M, Tougne C, Bozzotti P, Fulurija A, Duchosal MA, Lambert PH, et al. Unresponsiveness to
 219 lymphoid-mediated signals at the neonatal follicular dendritic cell precursor level contributes to delayed
 220 germinal center induction and limitations of neonatal antibody responses to T-dependent antigens. *J Immunol*
 221 2003;170:2824-32.

222 [14] Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. *Nat Rev Immunol*
 223 2009;9:185-94.

224 [15] Kakoulidou M, Ingelman-Sundberg H, Johansson E, Cagigi A, Farouk SE, Nilsson A, et al. Kinetics of antibody
 225 and memory B cell responses after MMR immunization in children and young adults. *Vaccine* 2013;31:711-7.

226 [16] Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. *N*
 227 *Engl J Med* 2007;357:1903-15.

228 [17] Rijkers GT, Dollekamp EG, Zegers BJ. The in vitro B-cell response to pneumococcal polysaccharides in
 229 adults and neonates. *Scand J Immunol* 1987;25:447-52.

230 [18] Gervassi AL, Horton H. Is infant immunity actively suppressed or immature? *Virology (Auckl)* 2014;2014:1-
 231 9.

232 [19] Eskola J, Kayhty H. Early immunization with conjugate vaccines. *Vaccine* 1998;16:1433-8.

233 [20] Siegrist CA. The challenges of vaccine responses in early life: selected examples. *J Comp Pathol* 2007;137
 234 *Suppl 1*:S4-9.

235 [21] Ota MO, Vekemans J, Schlegel-Haueter SE, Fielding K, Whittle H, Lambert PH, et al. Hepatitis B
 236 immunisation induces higher antibody and memory Th2 responses in new-borns than in adults. *Vaccine*
 237 2004;22:511-9.

238 [22] Vekemans J, Ota MO, Wang EC, Kidd M, Borysiewicz LK, Whittle H, et al. T cell responses to vaccines in
 239 infants: defective IFN γ production after oral polio vaccination. *Clin Exp Immunol* 2002;127:495-8.

240 [23] Ritz N, Strach M, Yau C, Dutta B, Tebruegge M, Connell TG, et al. A comparative analysis of polyfunctional T
 241 cells and secreted cytokines induced by Bacille Calmette-Guerin immunisation in children and adults. *PLoS One*
 242 2012;7:e37535.

243 [24] Gans H, Yasukawa L, Rinki M, DeHovitz R, Forghani B, Beeler J, et al. Immune responses to measles and
 244 mumps vaccination of infants at 6, 9, and 12 months. *J Infect Dis* 2001;184:817-26.

245 [25] Fadugba OO, Wang L, Chen Q, Halasa NB. Immune responses to pertussis antigens in infants and toddlers
 246 after immunization with multicomponent acellular pertussis vaccine. *Clin Vaccine Immunol* 2014;21:1613-9.

247 [26] Knuf M, Habermehl P, Cimino C, Petersen G, Schmitt HJ. Immunogenicity, reactogenicity and safety of a 7-
 248 valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib
 249 combination vaccine in healthy infants. *Vaccine* 2006;24:4727-36.

250 [27] Karlsson H, Hessel C, Rudin A. Innate immune responses of human neonatal cells to bacteria from the
 251 normal gastrointestinal flora. *Infect Immun* 2002;70:6688-96.

252 [28] Marchant A, Appay V, Van Der Sande M, Dulphy N, Liesnard C, Kidd M, et al. Mature CD8(+) T lymphocyte
 253 response to viral infection during fetal life. *J Clin Invest* 2003;111:1747-55.

254 [29] Huygens A, Lecomte S, Tackoen M, Olislagers V, Delmarcelle Y, Burny W, et al. Functional Exhaustion Limits
 255 CD4+ and CD8+ T-Cell Responses to Congenital Cytomegalovirus Infection. *J Infect Dis* 2015;212:484-94.

256 [30] Wong VC, Ip HM, Reesink HW, Lelie PN, Reerink-Brongers EE, Yeung CY, et al. Prevention of the HBsAg
 257 carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of
 258 hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. *Lancet*
 259 1984;1:921-6.

260 [31] Vekemans J, Amedei A, Ota MO, D'Elios MM, Goetghebuer T, Ismaili J, et al. Neonatal bacillus Calmette-
 261 Guerin vaccination induces adult-like IFN- γ production by CD4+ T lymphocytes. *Eur J Immunol*
 262 2001;31:1531-5.

263 [32] Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. Cross-reactive neuraminidase
264 antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. *PLoS Med*
265 2007;4:e59.

266 [33] Mansfield KL, Horton DL, Johnson N, Li L, Barrett AD, Smith DJ, et al. Flavivirus-induced antibody cross-
267 reactivity. *J Gen Virol* 2011;92:2821-9.

268 [34] Laupland KB, Davies HD, Low DE, Schwartz B, Green K, McGeer A. Invasive group A streptococcal disease in
269 children and association with varicella-zoster virus infection. Ontario Group A Streptococcal Study Group.
270 *Pediatrics* 2000;105:E60.

271 [35] O'Brien KL, Walters MI, Sellman J, Quinlisk P, Regnery H, Schwartz B, et al. Severe pneumococcal
272 pneumonia in previously healthy children: the role of preceding influenza infection. *Clin Infect Dis* 2000;30:784-
273 9.

274 [36] Mina MJ, Metcalf CJ, de Swart RL, Osterhaus AD, Grenfell BT. Long-term measles-induced
275 immunomodulation increases overall childhood infectious disease mortality. *Science* 2015;348:694-9.

276 [37] Blood-Siegfried J. The role of infection and inflammation in sudden infant death syndrome.
277 *Immunopharmacol Immunotoxicol* 2009;31:516-23.

278 [38] Kinney HC, Thach BT. The sudden infant death syndrome. *N Engl J Med* 2009;361:795-805.

279 [39] Essery SD, Raza MW, Zorgani A, MacKenzie DA, James VS, Weir DM, et al. The protective effect of
280 immunisation against diphtheria, pertussis and tetanus (DPT) in relation to sudden infant death syndrome.
281 *FEMS Immunol Med Microbiol* 1999;25:183-92.

282 [40] Vennemann MM, Hoffgen M, Bajanowski T, Hense HW, Mitchell EA. Do immunisations reduce the risk for
283 SIDS? A meta-analysis. *Vaccine* 2007;25:4875-9.

284 [41] Toro K, Meszaros R, Meszaros A, Csukas Z. Change in immunisation schedule and sudden infant death
285 syndrome in Hungary. *FEMS Immunol Med Microbiol* 2004;42:119-24.

286 [42] Muraille E. The unspecific side of acquired immunity against infectious disease: causes and consequences.
287 *Front Microbiol* 2015;6:1525.

288 [43] Flanagan KL, van Crevel R, Curtis N, Shann F, Levy O, Optimunize N. Heterologous ("nonspecific") and
289 sex-differential effects of vaccines: epidemiology, clinical trials, and emerging immunologic mechanisms. Clin
290 Infect Dis 2013;57:283-9.

291 [44] Kleinnijenhuis J, Quintin J, Preijers F, Benn CS, Joosten LA, Jacobs C, et al. Long-lasting effects of BCG
292 vaccination on both heterologous Th1/Th17 responses and innate trained immunity. J Innate Immun
293 2014;6:152-8.

294 [45] Gandhi NM, Morales A, Lamm DL. Bacillus Calmette-Guerin immunotherapy for genitourinary cancer. BJU
295 Int 2013;112:288-97.

296 [46] Ludwig AT, Moore JM, Luo Y, Chen X, Saltsgaver NA, O'Donnell MA, et al. Tumor necrosis factor-related
297 apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer
298 Res 2004;64:3386-90.

299 [47] Ota MO, Vekemans J, Schlegel-Haueter SE, Fielding K, Sanneh M, Kidd M, et al. Influence of
300 Mycobacterium bovis bacillus Calmette-Guerin on antibody and cytokine responses to human neonatal
301 vaccination. J Immunol 2002;168:919-25.

302 [48] Libraty DH, Zhang L, Woda M, Acosta LP, Obcena A, Brion JD, et al. Neonatal BCG vaccination is associated
303 with enhanced T-helper 1 immune responses to heterologous infant vaccines. Trials Vaccinol 2014;3:1-5.

304 [49] Ritz N, Mui M, Balloch A, Curtis N. Non-specific effect of Bacille Calmette-Guerin vaccine on the immune
305 response to routine immunisations. Vaccine 2013;31:3098-103.

306 [50] Villumsen M, Sorup S, Jess T, Ravn H, Relander T, Baker JL, et al. Risk of lymphoma and leukaemia after
307 bacille Calmette-Guerin and smallpox vaccination: a Danish case-cohort study. Vaccine 2009;27:6950-8.

308 [51] Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, et al. Bacille Calmette-Guerin induces
309 NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc
310 Natl Acad Sci U S A 2012;109:17537-42.

311 [52] Freyne B, Marchant A, Curtis N. BCG-associated heterologous immunity, a historical perspective:
312 experimental models and immunological mechanisms. Trans R Soc Trop Med Hyg 2015;109:46-51.

313 [53] Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Jacobs C, Xavier RJ, et al. BCG-induced trained immunity
314 in NK cells: Role for non-specific protection to infection. Clin Immunol 2014;155:213-9.

315 [54] Valentiner-Branth P, Perch M, Nielsen J, Steinsland H, Garly ML, Fischer TK, et al. Community cohort study
316 of *Cryptosporidium parvum* infections: sex-differential incidences associated with BCG and diphtheria-tetanus-
317 pertussis vaccinations. Vaccine 2007;25:2733-41.

318 [55] Rodrigues A, Fischer TK, Valentiner-Branth P, Nielsen J, Steinsland H, Perch M, et al. Community cohort
319 study of rotavirus and other enteropathogens: are routine vaccinations associated with sex-differential
320 incidence rates? Vaccine 2006;24:4737-46.

321 [56] Sorup S, Benn CS, Poulsen A, Krause TG, Aaby P, Ravn H. Live vaccine against measles, mumps, and rubella
322 and the risk of hospital admissions for nontargeted infections. JAMA 2014;311:826-35.

323 [57] Hollm-Delgado MG, Stuart EA, Black RE. Acute lower respiratory infection among Bacille Calmette-Guerin
324 (BCG)-vaccinated children. Pediatrics 2014;133:e73-81.

325 [58] Stensballe LG, Nante E, Jensen IP, Kofoed PE, Poulsen A, Jensen H, et al. Acute lower respiratory tract
326 infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for
327 girls community based case-control study. Vaccine 2005;23:1251-7.

328 [59] Sorup S, Benn CS, Stensballe LG, Aaby P, Ravn H. Measles-mumps-rubella vaccination and respiratory
329 syncytial virus-associated hospital contact. Vaccine 2015;33:237-45.

330 [60] Rowe J, Macaubas C, Monger TM, Holt BJ, Harvey J, Poolman JT, et al. Antigen-specific responses to
331 diphtheria-tetanus-acellular pertussis vaccine in human infants are initially Th2 polarized. Infect Immun
332 2000;68:3873-7.

333 [61] Brewer JM, Conacher M, Hunter CA, Mohrs M, Brombacher F, Alexander J. Aluminium hydroxide adjuvant
334 initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J Immunol
335 1999;163:6448-54.

336 [62] Fischer JE, Johnson JE, Johnson TR, Graham BS. Pertussis toxin sensitization alters the pathogenesis of
337 subsequent respiratory syncytial virus infection. J Infect Dis 2000;182:1029-38.

338 [63] Storsaeter J, Olin P, Renemar B, Lagergard T, Norberg R, Romanus V, et al. Mortality and morbidity from
 339 invasive bacterial infections during a clinical trial of acellular pertussis vaccines in Sweden. *Pediatr Infect Dis J*
 340 1988;7:637-45.

341 [64] Black SB, Cherry JD, Shinefield HR, Fireman B, Christenson P, Lampert D. Apparent decreased risk of
 342 invasive bacterial disease after heterologous childhood immunization. *Am J Dis Child* 1991;145:746-9.

343 [65] McKeever TM, Lewis SA, Smith C, Hubbard R. Vaccination and allergic disease: a birth cohort study. *Am J*
 344 *Public Health* 2004;94:985-9.

345 [66] Gruber C, Illi S, Lau S, Nickel R, Forster J, Kamin W, et al. Transient suppression of atopy in early childhood
 346 is associated with high vaccination coverage. *Pediatrics* 2003;111:e282-8.

347 [67] DeStefano F, Gu D, Kramarz P, Truman BI, Iademarco MF, Mullooly JP, et al. Childhood vaccinations and
 348 risk of asthma. *Pediatr Infect Dis J* 2002;21:498-504.

349 [68] Mullooly JP, Schuler R, Mesa J, Drew L, DeStefano F, team VSD. Wheezing lower respiratory disease and
 350 vaccination of premature infants. *Vaccine* 2011;29:7611-7.

351 [69] Hviid A, Melbye M. Measles-mumps-rubella vaccination and asthma-like disease in early childhood. *Am J*
 352 *Epidemiol* 2008;168:1277-83.

353 [70] Timmermann CA, Osuna CE, Steuerwald U, Weihe P, Poulsen LK, Grandjean P. Asthma and allergy in
 354 children with and without prior measles, mumps, and rubella vaccination. *Pediatr Allergy Immunol*
 355 2015;26:742-9.

356 [71] Arnoldussen DL, Linehan M, Sheikh A. BCG vaccination and allergy: a systematic review and meta-analysis.
 357 *J Allergy Clin Immunol* 2011;127:246-53, 53 e1-21.

358 [72] El-Zein M, Parent ME, Benedetti A, Rousseau MC. Does BCG vaccination protect against the development
 359 of childhood asthma? A systematic review and meta-analysis of epidemiological studies. *Int J Epidemiol*
 360 2010;39:469-86.

361 [73] Siegle JS, Hansbro N, Dong C, Angkasekwinai P, Foster PS, Kumar RK. Blocking induction of T helper type 2
 362 responses prevents development of disease in a model of childhood asthma. *Clin Exp Immunol* 2011;165:19-28.

363 [74] Bernsen RM, de Jongste JC, van der Wouden JC. Lower risk of atopic disorders in whole cell pertussis-
364 vaccinated children. *Eur Respir J* 2003;22:962-4.

365 [75] Nakajima K, Dharmage SC, Carlin JB, Wharton CL, Jenkins MA, Giles GG, et al. Is childhood immunisation
366 associated with atopic disease from age 7 to 32 years? *Thorax* 2007;62:270-5.

367 [76] Spycher BD, Silverman M, Egger M, Zwahlen M, Kuehni CE. Routine vaccination against pertussis and the
368 risk of childhood asthma: a population-based cohort study. *Pediatrics* 2009;123:944-50.

369 [77] Hawkes D, Benhamu J, Sidwell T, Miles R, Dunlop RA. Revisiting adverse reactions to vaccines: A critical
370 appraisal of Autoimmune Syndrome Induced by Adjuvants (ASIA). *J Autoimmun* 2015;59:77-84.

371 [78] Esposito S, Prada E, Mastrolia MV, Tarantino G, Codeca C, Rigante D. Autoimmune/inflammatory
372 syndrome induced by adjuvants (ASIA): clues and pitfalls in the pediatric background. *Immunol Res*
373 2014;60:366-75.

374 [79] Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune
375 manifestations after viral vaccines. *Vaccine* 2005;23:3876-86.

376 [80] Shann F. Nonspecific effects of vaccines and the reduction of mortality in children. *Clin Ther* 2013;35:109-
377 14.

378 [81] Aaby P, Kollmann TR, Benn CS. Nonspecific effects of neonatal and infant vaccination: public-health,
379 immunological and conceptual challenges. *Nat Immunol* 2014;15:895-9.

380 [82] Higgins JPT, Soares-Weiser K, Reingold A. Systematic review of the non-specific effects of BCG, DTP and
381 measles containing vaccines.
382 http://www.who.int/immunization/sage/meetings/2014/april/3_NSE_Epidemiology_review_Report_to_SAGE_14_Mar_FINAL.pdf 2014.

383
384 [83] Jensen ML, Dave S, Schim van der Loeff M, da Costa C, Vincent T, Leligidowicz A, et al. Vaccinia scars
385 associated with improved survival among adults in rural Guinea-Bissau. *PLoS One* 2006;1:e101.

386 [84] Lund N, Andersen A, Hansen AS, Jepsen FS, Barbosa A, Biering-Sorensen S, et al. The Effect of Oral Polio
387 Vaccine at Birth on Infant Mortality: A Randomized Trial. *Clin Infect Dis* 2015;61:1504-11.

388 [85] Vaugelade J, Pinchinat S, Guiella G, Elguero E, Simondon F. Non-specific effects of vaccination on child
389 survival: prospective cohort study in Burkina Faso. *BMJ* 2004;329:1309.

390 [86] Schurink-van't Klooster TM, Knol MJ, de Melker HE, van der Sande MA. Gender-specific mortality in DTP-
391 IPV- and MMR+/-MenC-eligible age groups to determine possible sex-differential effects of vaccination: an
392 observational study. *BMC Infect Dis* 2015;15:148.

393 [87] Aaby P, Jensen H, Walraven G. Age-specific changes in the female-male mortality ratio related to the
394 pattern of vaccinations: an observational study from rural Gambia. *Vaccine* 2006;24:4701-8.

395 [88] Benn CS, Aaby P. Diphtheria-tetanus-pertussis vaccination administered after measles vaccine: increased
396 female mortality? *Pediatr Infect Dis J* 2012;31:1095-7.

397 [89] Aaby P, Nielsen J, Benn CS, Trape JF. Sex-differential and non-specific effects of routine vaccinations in a
398 rural area with low vaccination coverage: an observational study from Senegal. *Trans R Soc Trop Med Hyg*
399 2015;109:77-84.

400 [90] Aaby P, Jensen H, Samb B, Cisse B, Sodemann M, Jakobsen M, et al. Differences in female-male mortality
401 after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis
402 and inactivated poliovirus: reanalysis of West African studies. *Lancet* 2003;361:2183-8.

403 [91] Rosario-Rosario G, Gareca M, Kincaid H, Knouse MC. Using locally derived seroprevalence data on measles,
404 mumps, rubella, and varicella by birth cohort to determine risks for vaccine-preventable diseases during
405 international travel. *J Travel Med* 2015;22:396-402.

406 [92] Phalgune DS, Yervadekar RC, Sharma HJ, Dhere RM, Parekh SS, Chandak AO, et al. Sero-surveillance to
407 assess rubella susceptibility and assessment of immunogenicity and reactogenicity of rubella vaccine in Indian
408 girls aged 18-24 years. *Hum Vaccin Immunother* 2014;10:2813-8.

409 [93] Scarbrough Lefebvre CD, Terlinden A, Standaert B. Dissecting the indirect effects caused by vaccines into
410 the basic elements. *Hum Vaccin Immunother* 2015;11:2142-57.

411 [94] Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years
412 after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study.
413 Lancet Infect Dis 2011;11:760-8.

414 [95] Sugerman DE, Barskey AE, Delea MG, Ortega-Sanchez IR, Bi D, Ralston KJ, et al. Measles outbreak in a
415 highly vaccinated population, San Diego, 2008: role of the intentionally undervaccinated. Pediatrics
416 2010;125:747-55.

417 [96] MacGillivray DM, Kollmann TR. The role of environmental factors in modulating immune responses in early
418 life. Front Immunol 2014;5:434.

419 [97] Daley D. The evolution of the hygiene hypothesis: the role of early-life exposures to viruses and microbes
420 and their relationship to asthma and allergic diseases. Curr Opin Allergy Clin Immunol 2014;14:390-6.

421 [98] McGovern ME, Canning D. Vaccination and all-cause child mortality from 1985 to 2011: global evidence
422 from the Demographic and Health Surveys. Am J Epidemiol 2015;182:791-8.

423 [99] Kristensen I, Aaby P, Jensen H. Routine vaccinations and child survival: follow up study in Guinea-Bissau,
424 West Africa. BMJ 2000;321:1435-8.

425 [100] Otto S, Mahner B, Kadow I, Beck JF, Wiersbitzky SK, Bruns R. General non-specific morbidity is reduced
426 after vaccination within the third month of life--the Greifswald study. J Infect 2000;41:172-5.

427 [101] Wilby KJ, Werry D. A review of the effect of immunization programs on antimicrobial utilization. Vaccine
428 2012;30:6509-14.

429 [102] Anekwe TD, Kumar S. The effect of a vaccination program on child anthropometry: evidence from India's
430 Universal Immunization Program. J Public Health (Oxf) 2012;34:489-97.

431 [103] Smith PJ, Humiston SG, Parnell T, Vannice KS, Salmon DA. The association between intentional delay of
432 vaccine administration and timely childhood vaccination coverage. Public Health Rep 2010;125:534-41.

433 [104] Hartel C, Adam N, Strunk T, Temming P, Muller-Steinhardt M, Schultz C. Cytokine responses correlate
434 differentially with age in infancy and early childhood. Clin Exp Immunol 2005;142:446-53.

435 [105] Krampera M, Vinante F, Tavecchia L, Morosato L, Chilosi M, Romagnani S, et al. Progressive polarization
436 towards a T helper/cytotoxic type-1 cytokine pattern during age-dependent maturation of the immune
437 response inversely correlates with CD30 cell expression and serum concentration. Clin Exp Immunol
438 1999;117:291-7.

439 [106] Clerici M, DePalma L, Roilides E, Baker R, Shearer GM. Analysis of T helper and antigen-presenting cell
440 functions in cord blood and peripheral blood leukocytes from healthy children of different ages. J Clin Invest
441 1993;91:2829-36.

442 [107] Siegrist CA. Neonatal and early life vaccinology. Vaccine 2001;19:3331-46.

443 [108] Teig N, Moses D, Gieseler S, Schauer U. Age-related changes in human blood dendritic cell
444 subpopulations. Scand J Immunol 2002;55:453-7.

445 [109] Upham JW, Lee PT, Holt BJ, Heaton T, Prescott SL, Sharp MJ, et al. Development of interleukin-12-
446 producing capacity throughout childhood. Infect Immun 2002;70:6583-8.

447 [110] Gantt S, Muller WJ. The immunologic basis for severe neonatal herpes disease and potential strategies
448 for therapeutic intervention. Clin Dev Immunol 2013;2013:369172.

449 [111] Anderson P, Ingram DL, Pichichero ME, Peter G. A high degree of natural immunologic priming to the
450 capsular polysaccharide may not prevent Haemophilus influenzae type b meningitis. Pediatr Infect Dis J
451 2000;19:589-91.

452 [112] Gans HA, Maldonado Y, Yasukawa LL, Beeler J, Audet S, Rinki MM, et al. IL-12, IFN-gamma, and T cell
453 proliferation to measles in immunized infants. J Immunol 1999;162:5569-75.

454 [113] Hambidge SJ, Newcomer SR, Narwaney KJ, Glanz JM, Daley MF, Xu S, et al. Timely versus delayed early
455 childhood vaccination and seizures. Pediatrics 2014;133:e1492-9.

456 [114] Guerra FA. Delays in immunization have potentially serious health consequences. Paediatr Drugs
457 2007;9:143-8.

458 [115] Aaby P, Ibrahim SA, Libman MD, Jensen H. The sequence of vaccinations and increased female mortality
459 after high-titre measles vaccine: trials from rural Sudan and Kinshasa. Vaccine 2006;24:2764-71.

460 [116] Grant CC, Roberts M, Scragg R, Stewart J, Lennon D, Kivell D, et al. Delayed immunisation and risk of
461 pertussis in infants: unmatched case-control study. *BMJ* 2003;326:852-3.

462 [117] Glanz JM, Narwaney KJ, Newcomer SR, Daley MF, Hambidge SJ, Rowhani-Rahbar A, et al. Association
463 between undervaccination with diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vaccine and risk of
464 pertussis infection in children 3 to 36 months of age. *JAMA Pediatr* 2013;167:1060-4.

465 [118] Nilsson L, Lepp T, von Segebaden K, Hallander H, Gustafsson L. Pertussis vaccination in infancy lowers the
466 incidence of pertussis disease and the rate of hospitalisation after one and two doses: analyses of 10 years of
467 pertussis surveillance. *Vaccine* 2012;30:3239-47.

468 [119] Quinn HE, Snelling TL, Macartney KK, McIntyre PB. Duration of protection after first dose of acellular
469 pertussis vaccine in infants. *Pediatrics* 2014;133:e513-9.

470 [120] Zamir CS, Dahan DB, Shoob H. Pertussis in infants under one year old: risk markers and vaccination
471 status--a case-control study. *Vaccine* 2015;33:2073-8.

472 [121] Kaaijk P, Kleijne DE, Knol MJ, Harmsen IA, Ophorst OJ, Rots NY. Parents' attitude toward multiple
473 vaccinations at a single visit with alternative delivery methods. *Hum Vaccin Immunother* 2014;10:2483-9.

474 [122] General recommendations on immunization --- recommendations of the Advisory Committee on
475 Immunization Practices (ACIP). *MMWR Recomm Rep* 2011;60:1-64.

476 [123] Gavioli R, Cellini S, Castaldello A, Voltan R, Gallerani E, Gagliardoni F, et al. The Tat protein broadens T cell
477 responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies
478 against AIDS. *Vaccine* 2008;26:727-37.

479 [124] White CJ, Stinson D, Staehle B, Cho I, Matthews H, Ngai A, et al. Measles, mumps, rubella, and varicella
480 combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to
481 children. Measles, Mumps, Rubella, Varicella Vaccine Study Group. *Clin Infect Dis* 1997;24:925-31.

482 [125] Czajka H, Schuster V, Zepp F, Esposito S, Douha M, Willems P. A combined measles, mumps, rubella and
483 varicella vaccine (Priorix-Tetra): immunogenicity and safety profile. *Vaccine* 2009;27:6504-11.

484 [126] Nascimento Silva JR, Camacho LA, Siqueira MM, Freire Mde S, Castro YP, Maia Mde L, et al. Mutual
485 interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps
486 and rubella. *Vaccine* 2011;29:6327-34.

487 [127] Stefano I, Sato HK, Pannuti CS, Omoto TM, Mann G, Freire MS, et al. Recent immunization against
488 measles does not interfere with the sero-response to yellow fever vaccine. *Vaccine* 1999;17:1042-6.

489 [128] Adu FD, Omotade OO, Oyedele OI, Ikusika O, Odemuyiwa SO, Onoja AL. Field trial of combined yellow
490 fever and measles vaccines among children in Nigeria. *East Afr Med J* 1996;73:579-82.

491 [129] Kanra G, Silier T, Yurdakok K, Yavuz T, Baskan S, Ulukol B, et al. Immunogenicity study of a combined
492 diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis vaccine used to reconstitute a freeze-dried
493 Haemophilus influenzae type b vaccine (DTaP-IPV//PRP-T) administered simultaneously with a hepatitis B
494 vaccine at two, three and four months of life. *Vaccine* 1999;18:947-54.

495 [130] Usonis V, Bakasenas V. Does concomitant injection of a combined diphtheria-tetanus-acellular pertussis -
496 hepatitis B virus - inactivated polio virus vaccine influence the reactogenicity and immunogenicity of
497 commercial Haemophilus influenzae type b conjugate vaccines? *Eur J Pediatr* 1999;158:398-402.

498 [131] Shinefield H, Black S, Thear M, Coury D, Reisinger K, Rothstein E, et al. Safety and immunogenicity of a
499 measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b
500 conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. *Pediatr Infect Dis*
501 *J* 2006;25:287-92.

502 [132] Zepp F, Behre U, Kindler K, Laakmann KH, Pankow-Culot H, Mannhardt-Laakmann W, et al.
503 Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a
504 booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-
505 Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months. *Eur J Pediatr*
506 2007;166:857-64.

507 [133] Iqbal S, Barile JP, Thompson WW, DeStefano F. Number of antigens in early childhood vaccines and
508 neuropsychological outcomes at age 7-10 years. *Pharmacoepidemiol Drug Saf* 2013;22:1263-70.

509 [134] Halsey NA, Boulos R, Mode F, Andre J, Bowman L, Yaeger RG, et al. Response to measles vaccine in
510 Haitian infants 6 to 12 months old. Influence of maternal antibodies, malnutrition, and concurrent illnesses. N
511 Engl J Med 1985;313:544-9.

512 [135] Ndikuyeze A, Munoz A, Stewart J, Modlin J, Heymann D, Herrmann KL, et al. Immunogenicity and safety
513 of measles vaccine in ill African children. Int J Epidemiol 1988;17:448-55.

514 [136] Dennehy PH, Saracen CL, Peter G. Seroconversion rates to combined measles-mumps-rubella-varicella
515 vaccine of children with upper respiratory tract infection. Pediatrics 1994;94:514-6.

516 [137] Offit PA, Quarles J, Gerber MA, Hackett CJ, Marcuse EK, Kollman TR, et al. Addressing parents' concerns:
517 do multiple vaccines overwhelm or weaken the infant's immune system? Pediatrics 2002;109:124-9.

518

519

520 **Figure Legends**

521 **Fig. 1. Early age antigen-specific immune response.**

522 Newborns have few APCs, which display an immature phenotype (1) and a low response to some TLR ligands
523 (2). This results in suboptimal antigen presentation (“signal 1”, 3) and co-stimulation through surface receptors
524 (“signal 2”, 4), as well as secretion of cytokines (“signal 3”, 5), in particular IL-12. Understimulated CD4⁺ T cells
525 show therefore a poor effector response, biased towards a Th2 type (6). B-cell responses are also impaired: T-
526 cell independent humoral responses develop only several months after birth (7) and even T-cell dependent
527 ones are weak due to a low expression of co-stimulatory molecules (8) and a limited development of T follicular
528 helper cells (9). The IgG production is limited as plasmacells are poorly functional (10), and produced
529 antibodies show reduced affinity maturation and shorter lifespan, in addition to be mainly constrained to the
530 IgG1 subclass (11). Defects at the level of APCs and CD4⁺ T-cell activation result in lower effector CD8 responses
531 against some antigens (12), also due to higher levels of suppressive populations (13). Further details and
532 literature references are presented in Table S1. Abbreviations: APC: antigen presenting cell; TLR: toll like
533 receptor; PAMP: Pathogen-associated molecular pattern; PRR: pattern recognition receptor.

534

535 **Table 1**

536 Immune-related heterologous effects of vaccines. Proposed mechanisms and literature references are shown
537 in Table S2

Factor	Effects
Susceptibility toward unrelated infections	BCG and MMR vaccines have been associated with lower risk of infections. DTP vaccine has been associated in some studies with an increased susceptibility to enteropathogens in girls but showed a protective effect against respiratory infections.
Adjuvant effect	BCG vaccine has been shown to improve responses toward vaccines administered at the same moment or later, and is used as immunotherapeutic against cancer.
SIDS	Some vaccines, and in particular DTP, have been associated with a reduced incidence of SIDS.
AIDs	Clinical and cohort studies failed in finding an increased prevalence of AIDs in subjects exposed to vaccines or adjuvants, suggesting that AIDs and ASIA are not generalized phenomena. Further studies are necessary to assess frequency and mechanisms of the reported cases.
Atopic disorder	MMR and BCG vaccines have been shown in some studies to decrease the risk of asthma. Conflicting results have been shown for DTP vaccine.
Overall mortality	BCG, MMR, Smallpox and oral Polio vaccines have been associated with a lower mortality rate. DTP vaccine has been associated with either increased and decreased non-specific mortality. However, current evidence is insufficient to support either of these conclusions.

538

539

540 **Table 2**

541 Common questions regarding interaction between vaccines and early age immune system

Questions	Reasons of Parents	Answer
May I decide to do only part of recommended vaccinations?	Some vaccine-preventable-diseases believed not so harmful or easy to contract	This choice may have different harmful consequences: <ul style="list-style-type: none">• Leave children unprotected for underestimated dangers.• Reverse the vaccination schedule with detrimental effects on heterologous immunity.• Weakening of the herd immunity → negative consequences for relatives (e.g. grandparents, siblings too young to be vaccinated, pregnant mothers) and immunocompromised persons.
Are vaccines weakening the immune system?	Fear of immunosuppressive effects of vaccines	<ul style="list-style-type: none">• Vaccines, in particular if administered on time and according suggested immunization schedules, favor the development of the immune system, enhancing protection not only against infections targeted by the immunization, but also to unrelated microbes.
My child is so young, should I delay vaccinations?	Fear that early age immune system may be too frail	<ul style="list-style-type: none">• The immune system of infants, although not fully mature, may easily bear the stimuli provided by vaccines, which are relatively weak if compared to the natural infections.• Innate and adaptive immunity in young children lack some specific functions that render them more susceptible to infections that, for the same reason, display high morbidity and mortality rate at early age. Vaccines are the only strategy to improve protection against these threats.• For some vaccines, children may display adult-like immune responses, even in early age.
Are multiple immunizations overwhelming the immune system?	Fear of overstimulating the immune system	<ul style="list-style-type: none">• The immune system may develop strong and competent antigen-specific immune response to hundreds of unrelated antigens at the same time.• All licensed combined vaccination and simultaneous administration of vaccines are always tested to assess that the co-administration is not inferior to administration of single components.

542

543